TPBG
UTHR icon

Turning Point Benefit Group’s United Therapeutics UTHR Stock Holding History

Turning Point Benefit Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$974 – 758
2025
Q4 		$974 Hold
2
– – ﹤0.01% 564
2025
Q3 		$876 Buy
+2
New +$673 ﹤0.01% 408

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Turning Point Benefit Group's UTHR Position: Q1 2026 in Review

Turning Point Benefit Group sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 2 shares — an estimated $974 sold.

Turning Point Benefit Group first reported a position in UTHR in Q3 2025 and held it in 2 quarters. The position peaked at $974 in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Turning Point Benefit Group reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 2 United Therapeutics shares in Q1 2026, an estimated $974.
  • Turning Point Benefit Group first reported a position in United Therapeutics in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's United Therapeutics position peaked at $974 in Q4 2025.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.